A61K 2039/542
Oral/gastrointestinal
Official title: {oral/gastrointestinal}
A61K2039/542 (Oral/gastrointestinal) appears on 838 US grants and 1,358 published applications in this corpus.
Search patents in A61K- Granted patents
- 838
- Published applications
- 1,358
- Assignees
- 708
- Inventors
- 2,322
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 3 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 5 | 0 |
| 1988 | 2 | 0 |
| 1989 | 3 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 4 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 5 | 0 |
| 1997 | 17 | 0 |
| 1998 | 14 | 0 |
| 1999 | 15 | 0 |
| 2000 | 19 | 0 |
| 2001 | 12 | 5 |
| 2002 | 19 | 31 |
| 2003 | 12 | 43 |
| 2004 | 12 | 44 |
| 2005 | 11 | 42 |
| 2006 | 24 | 32 |
| 2007 | 8 | 21 |
| 2008 | 12 | 41 |
| 2009 | 15 | 39 |
| 2010 | 13 | 46 |
| 2011 | 19 | 52 |
| 2012 | 24 | 56 |
| 2013 | 29 | 50 |
| 2014 | 33 | 50 |
| 2015 | 28 | 51 |
| 2016 | 53 | 75 |
| 2017 | 58 | 98 |
| 2018 | 57 | 57 |
| 2019 | 53 | 75 |
| 2020 | 55 | 67 |
| 2021 | 39 | 66 |
| 2022 | 40 | 57 |
| 2023 | 30 | 54 |
| 2024 | 32 | 88 |
| 2025 | 29 | 76 |
| 2026 | 19 | 42 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for preventing and treating virus infection15 Sep 2026US 12,734,234 B2University of Virginia Patent Foundation
- Immunogenic probiotic compositions and methods of use including in vaccination1 Sep 2026US 12,721,888 B2BiomEdit, Inc.
- Methods for preventing an immunoglobulin e-related disease25 Aug 2026US 12,714,736 B2My-Or Diagnostics Ltd.
- Edible plant exosome-like nanovectors for vaccination11 Aug 2026US 12,702,703 B2University of Louisville Research Foundation, Inc.
- Coronavirus vaccine based on controllable secretory expression of attenuated salmonella, preparation method therefor, and application thereof7 Jul 2026US 12,673,099 B2Jiangsu Target Biomedical Research Institute Co., Ltd.
- Pharmaceutical Composition for Vaccination against Cytomegalovirus Infections8 Oct 2026US 2026/0306606 A1Instar Technologies A.S.
- Method for inducing an immune response8 Oct 2026US 2026/0306617 A1Acclarent, Inc.
- Orally-delivered vaccines for domesticated and wild animals to prevent pathogen spread using recombinant probiotic bacteria1 Oct 2026US 2026/0295027 A1
- Saponin dmlt adjuvants and related uses1 Oct 2026US 2026/0295037 A1Q-Vant Biosciences, Inc.
- Universal vaccine for african swine fever virus (asfv) infections17 Sep 2026US 2026/0273039 A1DEI Biopharma
Most cited
By later US patents
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- Receptor specific transepithelial transport of therapeutics214US 6,030,613 ABrandeis University · 2000
- Method of treating or preventing type 1 diabetes by oral administration of insulin125US 5,763,396 AAutoimmune, Inc. · 1998
- Targeted and high density drug loaded polymeric materials123US 7,534,449 B2Yale University · 2009
- Antigen delivery system and method of production121US 6,838,089 B1AstraZeneca AB · 2005